Home>
Stocks>
Gufic BioSciences Ltd

Gufic BioSciences Ltd (GUFICBIO)

₹344.75▲2.91%

Get free price alerts. Set up your Free investment account to get Live Prices. >

Overview

Fundamentals

Q3 '23 Results

Technicals

News and Events

Gufic BioSciences Ltd share Performance

₹333.4
₹347.95
₹344.75
3.29%
Low
Day's Volatility:4.22%
High
0.93%
₹193.55
₹364.9
₹344.75
43.86%
Low
52 Weeks Volatility:49.70%
High
5.84%

Returns %
1 Month Return	+ 9.64 %
3 Month Return	+ 2.74 %
1 Year Return	+ 60.21 %

Market Stats
Previous Close	₹₹335.00
Open	₹₹335.00
Volume	₹2.69L
Upper Circuit	₹-
Lower Circuit	₹-
Market Cap	₹₹3,359.30Cr

Company Information

Gufic Biosciences (GBL) was established as a result of a reverse merger of itself and Central Finance at Rs 4042 per share, allowing for the company to be listed on the Bombay Stock Exchange. The Choksi and Gandhi family, the promoters of GBL, have a long-standing background in the pharmaceutical industry, having formed the joint venture company, Lyka Labs, in 1960. Gufic Biosciences, known as Gujarat Fine Chemicals, first operated in the bulk drug space, before moving into the formulation market. GBL currently offers ethical, herbal, consumer, and bulk drugs, both domestically and internationally, and have a history of creating leading brands. In 2000, GBL issued bonus equity shares at 5:2, and more recently the company has divested some of its assets in the ethical pharma business, with plans to reinvest in R&D activities, and to further invigorate the potential of the herbal and consumer product segments. With traditional knowledge in India, Gufic will be operating from a position of strength around those specific areas.

Share Price: ₹344.75 per share as on 17 May, 2024 04:01 PM
Market Capitalisation: ₹3,359.30Cr as of today
Revenue: ₹201.78Cr as on December 2023 (Q4 23)
Net Profit: ₹22.26Cr as on December 2023 (Q4 23)
Listing date: 19 Oct, 2004
Chairperson Name: Jayesh P Choksi

Organisation	Gufic BioSciences Ltd
Headquarters	Mumbai
Industry	Pharmaceuticals
E-voting on shares	Click here to vote

Key events for Gufic BioSciences Ltd

Gufic Biosciences' Top Executive Gains 10% Last Week - 27 Apr, 2024
Jayesh Choksi, the top key executive of Gufic Biosciences Limited, gained 10% last week. The company's insider ownership is positive but can also give immense power to a small group within the company.
Gufic Biosciences Forms Subsidiary in Dubai - 04 Apr, 2024
Gufic Biosciences has incorporated a wholly-owned subsidiary, Veira Life FZE, in Dubai to conduct the business of marketing, distribution, and sale of pharmaceutical products.

Fundamentals of Gufic BioSciences Ltd

Insights on Gufic BioSciences Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 7 days, GUFICBIO stock has moved up by 3.5%
POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 1.60% to 2.08% in Mar 2024 quarter
NO EFFECT
Against Peers
In the last 1 year, Zydus Lifesciences Ltd has given 94.5% return, outperforming this stock by 34.3%
NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 72.51% of holdings in Mar 2024 quarter
NO EFFECT
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 123.6% return, outperforming this stock by 56.0%
NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 25.29% to 25.17% in Mar 2024 quarter
NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 0.47% to 0.12% in Mar 2024 quarter

Mutual Fund Holdings

Funds	Holdings
Motilal Oswal Small Cap Fund Direct Growth	1.95%
SBI Healthcare Opportunities Fund Direct Growth	1.23%
ICICI Prudential Regular Savings Fund Direct Plan Growth	0.04%
Motilal Oswal Nifty Microcap 250 Index Fund Direct Growth	0.13%
WhiteOak Capital Pharma and Healthcare Fund Direct Growth	1.05%